Evaluating the effect of antidiabetic treatment on haemostatic and fibrinolytic parameters among type 2 diabetics in Ilorin, Nigeria

Background: Type 2 Diabetes Mellitus is a disease of epidemic proportions and many patients are at a great risk of premature mortality and complication of atherothrombotic disorders affecting coronary, cerebral and peripheral arterial trees. Increased Plasminogen Activator Inhibitor Type 1 inhibits...

Full description

Bibliographic Details
Main Authors: Abolarin AT, Olawumi HO, Durotoye IA, Olarinoye JK, Olufemi-Aworinde KJ
Format: Article
Language:English
Published: Nigerian Medical Association, Akwa Ibom State Branch 2022-09-01
Series:Ibom Medical Journal
Subjects:
Online Access:https://ibommedicaljournal.org/index.php/imjhome/article/view/270
_version_ 1827325108902952960
author Abolarin AT
Olawumi HO
Durotoye IA
Olarinoye JK
Olufemi-Aworinde KJ
author_facet Abolarin AT
Olawumi HO
Durotoye IA
Olarinoye JK
Olufemi-Aworinde KJ
author_sort Abolarin AT
collection DOAJ
description Background: Type 2 Diabetes Mellitus is a disease of epidemic proportions and many patients are at a great risk of premature mortality and complication of atherothrombotic disorders affecting coronary, cerebral and peripheral arterial trees. Increased Plasminogen Activator Inhibitor Type 1 inhibits fibrinolysis and predicts cardiovascular risk in those living with Type 2 Diabetes. This study aimed to determine the effect of antidiabetic treatment on haemostatic and fibrinolytic parameters among Type 2 Diabetic subjects in Ilorin. Methods: This was a comparative cross-sectional study involving 78 Type 2 diabetic patients, (39 treatment naïve, 39 treatment experienced). Full blood count was performed using Sysmex XP 300 while Prothrombin time was determined using one stage test of Owren. Activated partial thromboplastin time was determined by method of Proctor and Rapaport. Fibrinogen and Plasminogen Activator Inhibitor type-1 were assayed using AssayMax Human Fibrinogen ELISA and AssayMax Human PAI-1 ELISA kit. Data Analysis was done using SPSS version 25.0. Results: Mean PAI-1 levels were significantly higher in treatment naïve diabetics when compared to treatment experienced diabetics (2.44 ±2.57 vs 2.51±1.47 ng/ml p=0.002) as were fibrinogen levels (434.65±366.15 vs 482.24± 299.64mg /dl; p = 0.048). PAI -1 levels were lowest among diabetics treated with Metformin + DPP4 inhibitors, while fibrinogen levels were lowest among those treated with Metformin + sulfonylurea combination. Conclusion: Oral hypoglycaemic treatment, combination therapy in particular, improves fibrinolysis in type 2 diabetics thereby reducing the risk of cardiovascular disease in type 2 diabetes mellitus patients.
first_indexed 2024-03-07T14:16:29Z
format Article
id doaj.art-5e1154b1666f4694af16afea15a0220a
institution Directory Open Access Journal
issn 1597-7188
2735-9964
language English
last_indexed 2024-03-07T14:16:29Z
publishDate 2022-09-01
publisher Nigerian Medical Association, Akwa Ibom State Branch
record_format Article
series Ibom Medical Journal
spelling doaj.art-5e1154b1666f4694af16afea15a0220a2024-03-06T11:55:41ZengNigerian Medical Association, Akwa Ibom State BranchIbom Medical Journal1597-71882735-99642022-09-0115310.61386/imj.v15i3.270Evaluating the effect of antidiabetic treatment on haemostatic and fibrinolytic parameters among type 2 diabetics in Ilorin, NigeriaAbolarin AT0Olawumi HO1Durotoye IA2Olarinoye JK3Olufemi-Aworinde KJ4Department of Haematology and Blood Transfusion, Bowen University Teaching Hospital, Ogbomosho, Oyo State, NigeriaDepartment of Haematology and Blood Transfusion, University of Ilorin Teaching Hospital, Kwara State, NigeriaDepartment of Haematology and Blood Transfusion, University of Ilorin Teaching Hospital, Kwara State, NigeriaDepartment of Internal Medicine, University of Ilorin Teaching Hospital, Kwara State, NigeriaDepartment of Haematology, Ladoke Akintola University of Technology, Ogbomoso, Oyo State, Nigeria Background: Type 2 Diabetes Mellitus is a disease of epidemic proportions and many patients are at a great risk of premature mortality and complication of atherothrombotic disorders affecting coronary, cerebral and peripheral arterial trees. Increased Plasminogen Activator Inhibitor Type 1 inhibits fibrinolysis and predicts cardiovascular risk in those living with Type 2 Diabetes. This study aimed to determine the effect of antidiabetic treatment on haemostatic and fibrinolytic parameters among Type 2 Diabetic subjects in Ilorin. Methods: This was a comparative cross-sectional study involving 78 Type 2 diabetic patients, (39 treatment naïve, 39 treatment experienced). Full blood count was performed using Sysmex XP 300 while Prothrombin time was determined using one stage test of Owren. Activated partial thromboplastin time was determined by method of Proctor and Rapaport. Fibrinogen and Plasminogen Activator Inhibitor type-1 were assayed using AssayMax Human Fibrinogen ELISA and AssayMax Human PAI-1 ELISA kit. Data Analysis was done using SPSS version 25.0. Results: Mean PAI-1 levels were significantly higher in treatment naïve diabetics when compared to treatment experienced diabetics (2.44 ±2.57 vs 2.51±1.47 ng/ml p=0.002) as were fibrinogen levels (434.65±366.15 vs 482.24± 299.64mg /dl; p = 0.048). PAI -1 levels were lowest among diabetics treated with Metformin + DPP4 inhibitors, while fibrinogen levels were lowest among those treated with Metformin + sulfonylurea combination. Conclusion: Oral hypoglycaemic treatment, combination therapy in particular, improves fibrinolysis in type 2 diabetics thereby reducing the risk of cardiovascular disease in type 2 diabetes mellitus patients. https://ibommedicaljournal.org/index.php/imjhome/article/view/270FibrinolysisDiabetesMetformin
spellingShingle Abolarin AT
Olawumi HO
Durotoye IA
Olarinoye JK
Olufemi-Aworinde KJ
Evaluating the effect of antidiabetic treatment on haemostatic and fibrinolytic parameters among type 2 diabetics in Ilorin, Nigeria
Ibom Medical Journal
Fibrinolysis
Diabetes
Metformin
title Evaluating the effect of antidiabetic treatment on haemostatic and fibrinolytic parameters among type 2 diabetics in Ilorin, Nigeria
title_full Evaluating the effect of antidiabetic treatment on haemostatic and fibrinolytic parameters among type 2 diabetics in Ilorin, Nigeria
title_fullStr Evaluating the effect of antidiabetic treatment on haemostatic and fibrinolytic parameters among type 2 diabetics in Ilorin, Nigeria
title_full_unstemmed Evaluating the effect of antidiabetic treatment on haemostatic and fibrinolytic parameters among type 2 diabetics in Ilorin, Nigeria
title_short Evaluating the effect of antidiabetic treatment on haemostatic and fibrinolytic parameters among type 2 diabetics in Ilorin, Nigeria
title_sort evaluating the effect of antidiabetic treatment on haemostatic and fibrinolytic parameters among type 2 diabetics in ilorin nigeria
topic Fibrinolysis
Diabetes
Metformin
url https://ibommedicaljournal.org/index.php/imjhome/article/view/270
work_keys_str_mv AT abolarinat evaluatingtheeffectofantidiabetictreatmentonhaemostaticandfibrinolyticparametersamongtype2diabeticsinilorinnigeria
AT olawumiho evaluatingtheeffectofantidiabetictreatmentonhaemostaticandfibrinolyticparametersamongtype2diabeticsinilorinnigeria
AT durotoyeia evaluatingtheeffectofantidiabetictreatmentonhaemostaticandfibrinolyticparametersamongtype2diabeticsinilorinnigeria
AT olarinoyejk evaluatingtheeffectofantidiabetictreatmentonhaemostaticandfibrinolyticparametersamongtype2diabeticsinilorinnigeria
AT olufemiaworindekj evaluatingtheeffectofantidiabetictreatmentonhaemostaticandfibrinolyticparametersamongtype2diabeticsinilorinnigeria